- Home
- CRVS vs RIGL Comparison
CRVS vs RIGL Comparison
Compare CRVS & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRVS | RIGL |
|---|---|---|
| Founded | 2014 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 634.0M | 537.6M |
| IPO Year | 2016 | 2000 |
Fundamental Metrics
Financial Performance| Metric | CRVS | RIGL |
|---|---|---|
| Price | $8.38 | $42.34 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $13.75 | ★ $43.20 |
| AVG Volume (30 Days) | ★ 1.1M | 611.7K |
| Earning Date | 11-04-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 2698.26 |
| EPS | N/A | ★ 6.20 |
| Revenue | N/A | ★ $282,076,000.00 |
| Revenue This Year | N/A | $65.53 |
| Revenue Next Year | N/A | $0.22 |
| P/E Ratio | ★ N/A | $6.58 |
| Revenue Growth | N/A | ★ 79.13 |
| 52 Week Low | $2.54 | $14.63 |
| 52 Week High | $9.60 | $52.24 |
Technical Indicators
Market Signals| Indicator | CRVS | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 50.42 | 50.00 |
| Support Level | $8.31 | $40.52 |
| Resistance Level | $9.60 | $43.58 |
| Average True Range (ATR) | 0.54 | 3.01 |
| MACD | -0.09 | -1.21 |
| Stochastic Oscillator | 23.25 | 21.32 |
Price Performance
Historical ComparisonAbout CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.